Catalyst Capital Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Catalyst Capital Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-12,824	Closed	-$796K	–	370
2019 Q3	$796K	Buy	+12,824	New	+$805K	0.03%	134
2016 Q3	–	Sell	-96,180	Closed	-$7.16M	–	486
2016 Q2	$7.16M	Sell	96,180 -11,221	-10%	-$833K	1.32%	10
2016 Q1	$7.17M	Hold	107,401	–	–	1.21%	24
2015 Q4	$7.26M	Hold	107,401	–	–	1.05%	28
2015 Q3	$5.74M	Buy	+107,401	New	+$6.52M	0.77%	44
2015 Q1	–	Sell	-59,311	Closed	-$1.97M	–	493
2014 Q4	$1.97M	Buy	59,311 +35,832	+153%	+$1.17M	0.23%	96
2014 Q3	$688K	Buy	+23,479	New	+$779K	0.09%	202

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Catalyst Capital Advisors's LGND Position: Q4 2019 in Review

Catalyst Capital Advisors sold out of Ligand Pharmaceuticals (LGND) in Q4 2019, closing a stake of 12,824 shares — an estimated $796K sold.

Catalyst Capital Advisors first reported a position in LGND in Q3 2014 and held it in 7 quarters. The position peaked at $7.26M in Q4 2015. 266 funds tracked by Wall St. Rank hold LGND as of Q4 2019.

Catalyst Capital Advisors reported no remaining Ligand Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Catalyst Capital Advisors sold 12,824 Ligand Pharmaceuticals shares in Q4 2019, an estimated $796K.
Catalyst Capital Advisors first reported a position in Ligand Pharmaceuticals in Q3 2014 and held it in 7 quarters.
Catalyst Capital Advisors's Ligand Pharmaceuticals position peaked at $7.26M in Q4 2015.
266 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2019.

Based on Catalyst Capital Advisors's 13F filing for Q4 2019, filed 6 Feb 2020.